Gilead Sciences Inc. (NASDAQ:GILD) stock lagged behind benchmark indices this year but shows signs of reversal lately. The stock's robust positive momentum should continue on the back of Gilead's revived fortune in HCV market and encouraging developments in HIV.

drug Gilead HCV HIV market product quarter Revenue stock upcoming


Redhill Biopharma has a seemingly awesome pipeline of promising therapies, either ready to market or in late stages of development.

Redhill Biopharma (RDHL) has accumulated a powerful pipeline of late stage therapies.

approval EnteraGam GI market marketing operation pipeline product RedHill therapies


FibroGen Prices Follow-On Offering [0.04]

Posted on Aug. 16, 2017, 4:15 p.m. by 24/7 Wall St. @ [source]

Shares of FibroGen Inc. (NASDAQ: FGEN) saw a handy gain on Wednesday after the firm announced the pricing of its underwritten follow-on offering.

Under the terms of the offering, FibroGen is selling 8.0 million shares for $40.75 per share, with an overallotment option for an additional 1.2 million shares.

clinical commercialization development FibroGen firm offering Phase product shares Wednesday


International steel stocks are definitely out of favor currently, with valuations more healthy compared to domestic alternatives. In fact, some of the larger international players are, and continue to be, impacted by these moves.

China demand domestic export market POSCO product South Steel ton


Synergy Pharmaceuticals has the potential to be major player in the GI market, but the company may want to raise additional working capital. Take, for example, Synergy Pharmaceuticals Inc. (NASDAQ:SGYP).

capital current market Pharmaceuticals product Q2 quarter stock Synergy Trulance


We'd recommend capitalizing on any pullback in the stock to build a position before AI-driven growth starts having material impacts on Salesforce's financials. Part of the reason that investors under appreciate Salesforce is their fear that Salesforce's own market dominance means that >20% growth cannot continue forever, and once Salesforce posts a missed quarter, the stock will lose all luster.

application Einstein growth investors multiple position product Revenue Sales Cloud Salesforce


Despegar Files for IPO [-0.06]

Posted on Aug. 15, 2017, 2:10 p.m. by 24/7 Wall St. @ [source] has registered an F-1 form with the U.S. Securities and Exchange Commission (SEC) in regards with its initial public offering (IPO).

This is the leading online travel company in Latin America, known by its two brands, Despegar, the global brand, and Decolar, the Brazilian brand.

approximately bookings brand Despegar ended Latin offering online product travel


Endo Regaining Stride? [0.06]

Posted on Aug. 15, 2017, 12:29 p.m. by Long Investing Ideas from Seeking Alpha @ [source]

Endo International (ENDP) is a $1.7 billion market cap company focused on current and emerging medical needs with emphases in the areas of pain management, dermatology, urology, endocrinology, and orthopedics. The company will make installment payments 4Q 2017 through 4Q 2019, which Endo claims it is not aware of any claims that will not be handled by this accrual increase (but is possible that additional claims could be filed).

cellulite continue debt ENDP indication market product reported Revenue XIAFLEX


Eighteen months or so ago, I thought GEA Group (OTCPK:GEAGY) (G1AG.DE) looked fully valued despite the long-term attractiveness of a leading company in the food/beverage automation and equipment market.

GEA Group's dairy processing end-market, which is responsible for around 20% of sales, is likely to struggle for another year or so, but farming, food/beverage, brewing, pharmaceuticals, and industrial markets (including oil/gas) are looking better.

business costs equipment food food beverage GEA growth management market product


And finally, the market seems to catch on, testifying to the increased credibility that CEO Pera enjoys, and rightly so.

No marketing expense, but marketing through its community and professionals.

Amplifi competition margin market performance product Revenue term things Ubiquiti


The possibilities are discussed that these patents that Gilead has listed in the FDA's Orange Book on all four of its TAF-containing drugs could benefit the company in different ways. The ideas and possibilities presented here are my own and could be incorrect, possibly materially so.

combo drug EU generic GILD HIV HIV AIDS patent product TAF


In a sector where market-caps are cut in half daily and one good pick can make your portfolio for the year, Cumberland Pharmaceutical’s (CPIX) steady growth as a micro-cap biotech might raise some eyebrows. They stated their goal in to acquire and begin marketing one new product per year.

Cumberland Cumberland Pharmaceutical growth pharmaceutical pipeline product quarter Revenue sales stock


In a time when the grocery shopping experience is undergoing a change, in audience, service, and merchandising, a name in the food retail industry is making quite the footprint: Aldi.

Today, Aldi Nord operates 2,500 stores in Belgium, the Netherlands, Luxembourg, France, Poland, Spain, Denmark, and Portugal, as well as specialty grocery chain Trader Joe's in the U.S.; ALDI Süd operates 1,600 stores throughout the U.S., Austria, Slovenia, the United Kingdom, Ireland, Australia, and Switzerland.

Aldi brand chain customers food grocery product Shopping specialty store


After graphics specialist NVIDIA (NASDAQ: NVDA) reported strong financial results, shares of the company shed almost 7%.

That said, I've seen some speculation that NVIDIA's financial guidance for the coming quarter wasn't as good as it could've been if NVIDIA were planning to launch new gaming-oriented graphics processors based on its new Volta architecture, leading to the post-earnings decline in NVIDIA's stock price.

cards Gamer gaming GeForce graphics guidance NVIDIA processor product stock


The asset management industry in China is in its early phases of growth and there is plenty of potential for further gains.

Jupai Holdings (JP) is one of the emerging players in the huge and growing asset management market in China.

asset China estate fee fund Jupai management market Noah product


Why I Love Axon Enterprise [0.19]

Posted on Aug. 13, 2017, 1:35 p.m. by Latest Articles in Stocks @ [source]

There aren't a lot of companies on the market that have the top market share in a rapidly growing business where public policy trends are working in their favor, and that has a high-margin product to top it off. Axon won't make much, or any, money from selling body cameras to officers, but it will make a lot of money selling associated services that are required to maximize the value of those body cameras.

Axon body camera business law enforcement margin market product services stock year


INX to commence trading in gold options from August 30 [0.02]

Posted on Aug. 12, 2017, 5:13 p.m. by Markets @ [source]

BSE-promoted India (India INX) will launch trading in gold options from August 30, a move which will allow investors an opportunity to hedge their risk without worrying about daily market volatility.

India INX, which has received regulator Sebi's nod to launch the product, has estimated that gold options, along with other gold contracts, would clock a daily average turnover of Rs 35 million on the exchange's platform.

August Gold India INX launch options product received Sebi trading


Would Snap Merger With Twitter Solve Many Problems? [0.00]

Posted on Aug. 12, 2017, 12:35 p.m. by 24/7 Wall St. @ [source]

The two also-rans of social media are in deep trouble. A merger of the two could bring some level of benefit.

benefit companies development Facebook features future product SNAP Twitter user


VivaGel BV already approved for BV treatment in Europe.

This will speed up FDA approval for VivaGel BV for both treatment and prevention of recurrence of BV; global market is ~$1.75 billion.

AstraZeneca BV DEP market product recurrence Starpharma treatment treatment prevention VivaGel BV


The broad-based major European indices closed lower in Friday's trading session, as falling mining stocks and banks burdened the markets. Antofagasta Holdings closed 2.3% lower.

bank consumer index July June lost lower product rose year